NO306283B1 - Farmasöytisk blanding for nasal administrering omfattende polare morfinmetabolitter - Google Patents

Farmasöytisk blanding for nasal administrering omfattende polare morfinmetabolitter

Info

Publication number
NO306283B1
NO306283B1 NO942787A NO942787A NO306283B1 NO 306283 B1 NO306283 B1 NO 306283B1 NO 942787 A NO942787 A NO 942787A NO 942787 A NO942787 A NO 942787A NO 306283 B1 NO306283 B1 NO 306283B1
Authority
NO
Norway
Prior art keywords
pct
polar
agents
morphine
nasal administration
Prior art date
Application number
NO942787A
Other languages
English (en)
Norwegian (no)
Other versions
NO942787D0 (no
NO942787L (no
Inventor
Lisbeth Illum
Original Assignee
Danbiosyst Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk Ltd filed Critical Danbiosyst Uk Ltd
Publication of NO942787D0 publication Critical patent/NO942787D0/no
Publication of NO942787L publication Critical patent/NO942787L/no
Publication of NO306283B1 publication Critical patent/NO306283B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO942787A 1992-02-05 1994-07-27 Farmasöytisk blanding for nasal administrering omfattende polare morfinmetabolitter NO306283B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929202464A GB9202464D0 (en) 1992-02-05 1992-02-05 Composition for nasal administration
PCT/GB1993/000228 WO1993015737A1 (en) 1992-02-05 1993-02-04 Compositions for nasal administration containing polar metabolites of opioid analgesics

Publications (3)

Publication Number Publication Date
NO942787D0 NO942787D0 (no) 1994-07-27
NO942787L NO942787L (no) 1994-07-27
NO306283B1 true NO306283B1 (no) 1999-10-18

Family

ID=10709891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942787A NO306283B1 (no) 1992-02-05 1994-07-27 Farmasöytisk blanding for nasal administrering omfattende polare morfinmetabolitter

Country Status (12)

Country Link
US (1) US5629011A (de)
EP (1) EP0625044B1 (de)
JP (1) JP3958352B2 (de)
AT (1) ATE171872T1 (de)
AU (1) AU665806B2 (de)
CA (1) CA2127805C (de)
DE (1) DE69321458T2 (de)
DK (1) DK0625044T3 (de)
ES (1) ES2123660T3 (de)
GB (2) GB9202464D0 (de)
NO (1) NO306283B1 (de)
WO (1) WO1993015737A1 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
GB2282758A (en) * 1993-08-23 1995-04-19 Euro Celtique Sa Oral morphine-6-glucuronide compositions
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
EP0788801A1 (de) * 1994-07-20 1997-08-13 Toyama Chemical Co., Ltd. Orale salbe mit verzögerter freisetzung
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6403602B1 (en) * 1997-02-20 2002-06-11 The University Of Kentucky Research Foundation Morphine-6-sulfate analogues and their use for the treatment of pain
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
JP2005281315A (ja) * 1997-07-02 2005-10-13 Aventis Pharmaceuticals Holdings Inc 水性薬理組成物
IL133882A0 (en) * 1997-07-18 2001-04-30 Bayer Ag Process for making an intranasal drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
AU753278B2 (en) * 1998-02-25 2002-10-10 Abbott Laboratories Butorphanol sustained release formulations
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6608073B1 (en) * 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
FR2787029A1 (fr) * 1998-12-09 2000-06-16 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de vitamine b12 pour la delivrance d'agents actifs au systeme nerveux central
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
WO2000076477A1 (en) * 1999-06-16 2000-12-21 Nastech Pharmaceutical Co., Inc. Methods and compositions for treating breakthrough pain
PL352556A1 (en) * 1999-06-16 2003-08-25 Nastech Pharmaceutical Co Pharmaceutical formulations and methods comprising intranasal morphine
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6863896B1 (en) * 1999-10-26 2005-03-08 Chiron Corporation Plant lectins as mucosal adjuvants
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1935421A1 (de) * 2000-02-08 2008-06-25 Euro-Celtique S.A. Kontrolliert freigesetzte Zusammensetzungen mit einem Opioid-Agonisten und einem Opioid-Antagonisten
DK2283842T3 (en) * 2000-02-08 2015-05-26 Euro Celtique Sa Oral opioid agonist formulations secured against forgery
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
AU2001286518A1 (en) * 2000-08-15 2002-02-25 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
BR0205721A (pt) * 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
ATE375786T1 (de) 2001-08-16 2007-11-15 Cmp Therapeutics Ltd Chitin-mikropartikel und ihre medizinische verwendung
EP1429730A4 (de) * 2001-09-26 2010-06-16 Penwest Pharmaceuticals Compan Opioid-formulierungen mit verringertem missbrauchspotenzial
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
WO2003066068A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Hpma-polyamine conjugates and uses therefore
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2006021996A (ja) * 2002-07-04 2006-01-26 Dainippon Sumitomo Pharma Co Ltd 置換ヒドロキシピリジン化合物の抱合体
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US7445769B2 (en) * 2002-10-31 2008-11-04 Cadbury Adams Usa Llc Compositions for removing stains from dental surfaces and methods of making and using the same
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
JP2006525354A (ja) * 2003-05-01 2006-11-09 アルキメデス・ディヴェロップメント・リミテッド Ｌｈ−ｒｈアナログロイプロイドの経鼻投与
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
US20050283004A1 (en) * 2004-06-18 2005-12-22 Hopax Chemicals Manufacturing Co., Ltd. Alkylsulfonated polyaminosaccharides
GB0416328D0 (en) * 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
US7641892B2 (en) * 2004-07-29 2010-01-05 Cadburry Adams USA, LLC Tooth whitening compositions and delivery systems therefor
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
EP2056800B1 (de) 2005-08-26 2015-12-09 The Board Of Trustees Of The Leland Stanford Junior University Therapieverfahren zur arzneiabgabe gegen trigeminale schmerzen
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
NZ571965A (en) * 2006-03-30 2012-02-24 Engene Inc Chitosan-based nanoparticles and methods for transfecting gut cells in vivo
PT2526932T (pt) 2006-06-19 2017-08-10 Alpharma Pharmaceuticals Llc Composição farmacêutica
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2112923A1 (de) 2007-01-22 2009-11-04 Targacept Inc. Intranasale, orale und sublinguale verabreichung von metanikotin-analogen
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009079521A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
TWI486161B (zh) 2011-05-13 2015-06-01 Euro Celtique Sa 含那若松（ｎａｌｏｘｏｎｅ）的鼻內藥物劑型
WO2013011477A1 (en) 2011-07-20 2013-01-24 Torrent Pharmaceuticals Ltd Pharmaceutical invention of tapentadol
WO2015138919A1 (en) 2014-03-14 2015-09-17 The University Of North Carolina At Chapel Hill Small molecules for inhibiting male fertility
CA2972975A1 (en) 2015-01-07 2016-07-14 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
FR3032353B1 (fr) 2015-02-06 2017-03-10 Jacques Seguin Composition pharmaceutique et dispositif pour le traitement de la douleur
US20180110725A1 (en) * 2016-10-21 2018-04-26 Somniferum Labs LLC Compositions, methods and kits for the safe inhaled delivery of targeted opioids for the treatment of pain and addiction
RS65027B1 (sr) 2017-01-11 2024-01-31 Torrent Pharmaceuticals Ltd Nazalna kompozicija tapentadola
US10292948B2 (en) 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition
US11304968B2 (en) 2018-11-16 2022-04-19 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide
US10639294B2 (en) 2018-10-02 2020-05-05 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite
CN110257025B (zh) * 2019-07-03 2020-07-03 中国石油大学(华东) 水基钻井液用环糊精微球超高温降滤失剂及其制备方法以及水基钻井液和应用
EP4230206A1 (de) * 2020-10-15 2023-08-23 Pharmbiotest Poland SP.ZO.O. Pharmazeutische zusammensetzung auf basis von nalbuphin und/oder salzen davon zur nasalen verabreichung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
DE3602370A1 (de) * 1986-01-27 1987-08-06 Chrubasik Sigrun Verwendung von analgetica durch inhalation
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
AU7547891A (en) * 1990-03-30 1991-10-30 Yasunori Morimoto Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
FR2665357B1 (fr) * 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
JPH07505655A (ja) * 1992-04-13 1995-06-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ アルコール乱用の処置のためのデルタオピオイドレセプター選択的ベンジリデン置換化モルヒナン

Also Published As

Publication number Publication date
US5629011A (en) 1997-05-13
ATE171872T1 (de) 1998-10-15
GB9413102D0 (en) 1994-08-31
EP0625044B1 (de) 1998-10-07
JPH07503481A (ja) 1995-04-13
GB2277682A (en) 1994-11-09
EP0625044A1 (de) 1994-11-23
GB2277682B (en) 1995-12-20
AU665806B2 (en) 1996-01-18
DK0625044T3 (da) 1999-06-21
CA2127805C (en) 2004-03-30
DE69321458T2 (de) 1999-03-18
DE69321458D1 (de) 1998-11-12
CA2127805A1 (en) 1993-08-19
GB9202464D0 (en) 1992-03-18
NO942787D0 (no) 1994-07-27
NO942787L (no) 1994-07-27
AU3458093A (en) 1993-09-03
WO1993015737A1 (en) 1993-08-19
JP3958352B2 (ja) 2007-08-15
ES2123660T3 (es) 1999-01-16

Similar Documents

Publication Publication Date Title
NO306283B1 (no) Farmasöytisk blanding for nasal administrering omfattende polare morfinmetabolitter
IE860306L (en) Drug delivery system
EP0788346A4 (de) Emulgierte arzneistoffabgabesysteme
NO306847B1 (no) Blanding for nasal administrering av nikotin
CA2181742A1 (en) Reduction of skin irritation during electrotransport delivery
EP0995434A3 (de) Medizinische Aerosolformulierungen
AU5954596A (en) Intravitreal microsphere drug delivery and method of prepara tion
AU5255996A (en) Topical formulation for local delivery of a pharmaceutically active agent
NO993195D0 (no) Blanding for administrasjon av medikamenter
AU4373993A (en) Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
DE69311395T2 (de) Sphäroidische Arzneimittelformulierung
CA2136985A1 (en) Novel Use of Hexaflumuron as a Termiticide
AU3533395A (en) Oral sustained-release preparation
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
EP0160501A3 (de) Intranasale Zusammenstellung mit verzögerter Freigabe und Gebrauchsanweisung
PT1003477E (pt) Sistema terapeutico transdermico (tts), contendo polimeros de (met)acrilato com grupos amonio para administracao de levonorgestrel
FI944441A0 (fi) Määriteltyjä lipidejä sisältävä farmaseuttinen kantojärjestelmä
AU1812395A (en) Film coated tablet of paracetamol and domperidone
CA2125281A1 (en) Immediate-effect ibuprofen-containing medicament and its use
KR950028767A (ko) 피부통과 투약을 위한 신규의 약제학적 투여 형태
GB2305606A (en) Drug delivery composition for the nasal administration of antiviral agents
AU9221898A (en) Pharmaceutical coating composition and method of use
AU7687896A (en) Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
UA41378C2 (uk) Здатний до емульгування у воді рідкий засіб з інсектицидною активністю

Legal Events

Date Code Title Description
MK1K Patent expired